We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Nontoxic QD Nanoparticles Inhibit Cancer Cell Growth

By LabMedica International staff writers
Posted on 29 May 2018
An environmentally friendly method has been developed for the production of quantum dot nanoparticles, which have antimicrobial properties and demonstrate potential for cancer diagnosis and treatment.

Low-dimensional (<10 nanometer) semiconductor quantum dots (QDs) have received great attention for potential use in biomedical applications (diagnosis and therapy) for which larger nanoparticles (>10 nanometers) are not suitable. More...
However, the chemical synthesis of quantum dots is complicated, expensive, and has toxic side effects.

To avoid these toxic effects, investigators at Swansea University (United Kingdom) developed a non-toxic plant-based alternative method of producing quantum dots, using tealeaf extract. Extracts derived from tealeaves (Camellia sinensis) contain a wide variety of compounds, including polyphenols, amino acids, vitamins, and antioxidants. The investigators added tealeaf extract to a mixture of cadmium sulfate (CdSO4) and sodium sulfide (Na2S) and allowed the solution to incubate until quantum dots formed.

The investigators examined the biological activity of these CdS QDs in different applications, namely, (a) antibacterial activity, (b) bioimaging, and (c) apoptosis of lung cancer cells. The antibacterial activity of the CdS QDs was evaluated and showed that CdS QDs effectively inhibited bacterial growth.

The investigators further reported in the March 9, 2018, online edition of the journal Applied Nano Materials that the quantum dots exhibited cytotoxicity toward A549 lung cancer cells when compared to a control (no QD treatment). The cytotoxic effect on A549 cancer cells was comparable to that of a standard drug, cisplatin. Furthermore, these CdS QDs produced high-contrast fluorescence images of A549 cancer cells indicating a strong interaction with the cancer cell.

To further understand the role of CdS QDs in bioimaging and the cytotoxic effect in A549 cells, the investigators performed fluorescence emission and flow cytometry analyses. The flow cytometry analysis confirmed that the CdS QDs were arresting A549 cell growth at the S phase of the cell cycle, inhibiting further growth of these lung cancer cells.

Senior author Dr. Sudhagar Pitchaimuthu, senior research fellow in engineering at Swansea University, said, "Our research confirmed previous evidence that tea leaf extract can be a non-toxic alternative to making quantum dots using chemicals. The real surprise, however, was that the dots actively inhibited the growth of the lung cancer cells. We had not been expecting this. The CdS quantum dots derived from tealeaf extract showed exceptional fluorescence emission in cancer cell bioimaging compared to conventional CdS nanoparticles. Quantum dots are therefore a very promising avenue to explore for developing new cancer treatments. Building on this exciting discovery, the next step is to scale up our operation, hopefully with the help of other collaborators. We want to investigate the role of tealeaf extract in cancer cell imaging, and the interface between quantum dots and the cancer cell. We would like to set up a "quantum dot factory" which will allow us to explore more fully the ways in which they can be used."

Related Links:
Swansea University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.